SCHEMBL19970051

SCHEMBL19970051

CN1CCc2c(n(Cc3ccccc3)c3ccccc23)C1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.80
HTR1A P08908 1/20 0.80
ADRA2A P08913 1/20 0.80
CHRM1 P11229 1/20 0.80
DRD1 P21728 1/20 0.80
SLC6A2 P23975 1/20 0.80
SLC6A4 P31645 1/20 0.80
ADRA1A P35348 1/20 0.80
OPRM1 P35372 1/20 0.80
DRD3 P35462 1/20 0.80
SLC6A3 Q01959 1/20 0.80
KCNH2 Q12809 1/20 0.80
ALDH1A1 P00352 1/20 0.78
GAA P10253 1/20 0.78
TSHR P16473 1/20 0.78
HDAC6 Q9UBN7 6/20 0.69
HDAC1 Q13547 4/20 0.69
HDAC3 O15379 2/20 0.69
HDAC2 Q92769 2/20 0.69
HDAC10 Q969S8 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20960970 0.91 HDAC6 (0.69) CHRM2HTR1AADRA2ACHRM1DRD1
Mebhydrolin SCHEMBL29808874 0.89 ADRA2A (1.00) CHRM2HTR1AADRA2ACHRM1DRD1
Mebhydrolin SCHEMBL29802 0.89 ADRA2A (1.00) CHRM2HTR1AADRA2ACHRM1DRD1
Mebhydrolin SCHEMBL2141004 0.88 ALDH1A1 (1.00) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL20340631 0.87 MAOA (0.67) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL12938922 0.85 HDAC6 (0.78) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL16624342 0.85 CHRM2 (0.59) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL20960968 0.84 HDAC6 (0.77) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL8038611 0.84 CHRM2 (0.85) CHRM2HTR1AADRA2ACHRM1DRD1
SCHEMBL17517481 0.83 MAOA (0.79) CHRM2HTR1AADRA2ACHRM1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10322122-B2 Methods and compositions for treating degenerative and ischemic disorders THE GENERAL HOSPITAL CORPORATION (US) 2019-06-18 US disclosed
US-20180071279-A1 METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS THE GENERAL HOSPITAL CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071279-A1 METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS PINK1, PC, PCK2 CHRM2 958/4885HTR1A 821/4885ADRA2A 1645/4885
US-10322122-B2 Methods and compositions for treating degenerative and ischemic disorders PINK1, PC, PCK2 CHRM2 958/4885HTR1A 821/4885ADRA2A 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.